

## InterVenn Biosciences establishes Malaysia as regional hub for delivery



03/08/2022 12:12 PM

KUALA LUMPUR, Aug 3 (Bernama) – InterVenn Biosciences, a United States (US)-based clinical technology company, has established Malaysia as the regional hub for delivery of its medical healthcare services and products in ASEAN and Asia-Pacific regions.

InterVenn Biosciences said in preparing Malaysia to be the regional hub, it has secured a new 1,207.73 square metres office and laboratory located at Technology Park Malaysia, Kuala Lumpur, which is its only other laboratory outside of the US outfitted with state-of-the-art equipment.

“This facility provides an opportunity to tap into and grow the locally based biomedical talent in Malaysia,” it said in a statement today.

It said the company has a wide range of breakthrough tests for various types of cancers and diseases in the pipeline while its non-traditional approach to epi-proteomics is a marriage of mass spectrometry and artificial intelligence/machine learning (AI/ML).

"The top-prized winner of the prestigious CIO Review APAC Top Artificial Intelligence Company Award 2022, InterVenn Biosciences' key services and products are involved in research and development and revolutionising the fight against cancers and diseases through deployment of emerging technologies such as AI, spectrometry and ML algorithms to help cancer patients, doctors, scientists and healthcare community," it said.

Apart from its Malaysian expansion, the company said it has also recently spread its wings in San Diego, South California, US to boost its commercial and support teams to serve and tap the thriving life science community while its new presence in Melbourne, Australia would enable it to increase scientific collaborations with talents in AI/ML and informatics to have broader access to clinical samples and biobanking.

Additionally, it said its expanded presence in the Philippines offered upscaling of its software engineering and IT capabilities to support current and future development and commercial activities.

Chief executive officer and co-founder Aldo Carrascoso said key decisions in selecting Malaysia also lie in his vision to be closer with the patients and experts in the region to accelerate the mission that no one should ever be blindsided by the disease.

"Here at InterVenn, maladies are holistically understood, adequately controlled and even manipulated to benefit all.

"We exist today to revisit the health-disease spectrum with an unprecedented and exclusive focus on 'glyco' while incorporating the latest technological advancements and fully supporting our Malaysian office with those tools," he said.

InterVenn Malaysia's general manager Fadzhairi Jabar said a part of this growth was a result of the support of regional collaborators and partners as well as recognition given by the relevant government agency and research institutions.

"InterVenn was certified as part of Bioeconomy Corporation's BBA (Bio-based Accelerator) programme last year, expanding and fostering this interaction as aligned with our vision towards creating a world where everyone in the region benefits from our goal," he added.